Akorn, Hyaluron Sign Development/Supply Pact

Akorn, Inc. and Hyaluron Contract Manufacturing (HCM) have signed a development and supply agreement for two ANDA injectable suspension products.

One of the products is an injectable sustained release pharmaceutical, which will be available in both prefilled syringe and vial configurations. The second ANDA product is an anti-inflammatory and will be available in multiple packaging configurations. Hyaluron will manufacture both drug products for Akorn, which will be responsible for marketing and distributing them within the U.S. Akorn will own both ANDAs, coordinate the bioequivalency clinical trials and prepare the ANDA regulatory filings. Financial terms of the agreement were not disclosed. The products are expected to launch in 2010.

Arthur S. Przybyl, Akorn’s president and chief executive officer stated “We are excited to be working with Hyaluron on these two opportunities. Both products will be key growth drivers for our company, similar to our upcoming Vancomycin capsule, Tetanus Diphtheria Vaccine and Akten product launches. The addition of injectable suspensions to Akorn’s portfolio complements our line of injectable drug products that includes both proprietary and generic drugs.”

Shawn Kinney, Hyaluron’s president stated, “Our decision to partner with Akorn is reflective of our commitment to provide our clients with innovative solutions to all their formulation and filling needs. We look forward to working with Akorn, and to the opportunities this collaboration presents to make a lasting contribution to the market for sterile injectable products.”